Alagözlü H, Gültekin F, Candan F
Department of Internal Medicine, Cumhuriyet University, Sivas, Turkey.
Nutr Metab Cardiovasc Dis. 2000 Aug;10(4):204-8.
In this study, we investigated the levels of apolipopotein-AI (apo-AI), apolipoprotein (apo-B), triglyceride (TG), high-density-lipoprotein-cholesterol (HDL-C), low-density-lipoprotein-cholesterol (LDL-C), total cholesterol, lipoprotein(a) in a group of non-obese, type 2 diabetes mellitus patients with different types of treatment and a control group of non-obese, non-diabetic subjects.
Patients were divided into three groups according to their treatment types: insulin, sulphonylurea and untreated groups. All groups were similar in sex, weights, known duration of diabetes and habits. Each group consisted of 30 subjects. There were no differences in apo-AI, apo-B and TG levels (p > 0.05), whereas HDL-C levels in the untreated group were significantly lower than those of the other groups (p < 0.05). Lp(a) levels in the untreated group were higher than in the other (p < 0.05).
Gaining metabolic control in diabetes mellitus is crucial in pulling back lipid, lipoprotein and apolipoprotein levels to a desired level and in attenuating CAD (coronary artery disease) risk factors, and also in preventing CAD. Lp(a) levels in particular are decreased by insulin or sulfonylurea in non-obese patients with type 2 diabetes mellitus.
在本研究中,我们调查了一组非肥胖的2型糖尿病患者在接受不同类型治疗时以及非肥胖、非糖尿病对照人群中载脂蛋白A-I(apo-AI)、载脂蛋白(apo-B)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、总胆固醇、脂蛋白(a)的水平。
患者根据治疗类型分为三组:胰岛素组、磺脲类药物组和未治疗组。所有组在性别、体重、已知糖尿病病程和生活习惯方面相似。每组由30名受试者组成。apo-AI、apo-B和TG水平无差异(p>0.05),而未治疗组的HDL-C水平显著低于其他组(p<0.05)。未治疗组的Lp(a)水平高于其他组(p<0.05)。
糖尿病患者实现代谢控制对于将脂质、脂蛋白和载脂蛋白水平恢复到理想水平、减轻冠状动脉疾病(CAD)危险因素以及预防CAD至关重要。尤其是在非肥胖的2型糖尿病患者中,胰岛素或磺脲类药物可降低Lp(a)水平。